Stock MNKD MANNKIND CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Other languages MannKind Corporation

Equities

MNKD

US56400P7069

Real-time Estimate Cboe BZX
Other stock markets
 15:50:44 29/04/2024 BST 		5-day change 1st Jan Change
4.315 USD +2.01% Intraday chart for MannKind Corporation +5.60% +19.23%
12:36pm MannKind Gets FDA Clearance for Clofazimine IND Application DJ
12:05pm MannKind Corporation Announces IND Clearance from U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial Lung Disease CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
MannKind Corporation Announces IND Clearance from U.S. FDA to Start Phase 3 Study of Clofazimine Inhalation Suspension for Nontuberculous Mycobacterial Lung Disease
MannKind Corporation Appoints Steven B. Binder as Executive Vice President, Special Projects
MannKind Corporation Announces INHALE-3 Study?s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections and Insulin Pumps
MannKind Corporation Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
MannKind Corporation Announces Enrollment Goal Completion of INHALE-1 Pediatric Diabetes Trial Utilizing Afrezza®
Sector Update: Health Care Stocks Decline Pre-Bell Tuesday
MannKind Sells 1% Royalty on Tyvaso DPI Net Sales for Up to $200 Million
MannKind Restructures Supply Agreement with Amphastar Pharmaceuticals
Mannkind Insider Sold Shares Worth $801,928, According to a Recent SEC Filing
MannKind Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
MannKind Corporation Announces Completion of Enrollment in U.S. Phase 4 Inhale-3 Clinical Trial in Patients Living with Type 1 Diabetes
MannKind Receives US Patent for Clofazimine Inhalation Suspension to Treat Lung Disease
Sector Update: Health Care Stocks Mixed Premarket Tuesday
MannKind Reports Q2 Breakeven, Revenue Rises
MannKind Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
MannKind's German Manufacturing Facility Caught Fire
MannKind Starts Type 1 Diabetes Trial to Evaluate Effect of Inhaled Insulin on Mealtime Control
Mannkind Corporation Launches Inhale-3 Study to Address the Most Important Unmet Need in Adults Living with Type 1 Diabetes
MannKind Hires Burkhard Blank as CMO
Dr. Burkhard Blank Joins MannKind Corporation as Executive Vice President of Research & Development and Chief Medical Officer
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MNKD Stock
  4. News MannKind Corporation
  5. Other languages